Sun Pharmaceuticals was set up in 1983 and the company started off with only 5 products to cure psychiatric illness. Sun Pharma is best known worldwide as the manufacture of specialty Active Pharmaceuticals Ingredients and formulations.
However, the company is also concerned with chronic treatments such as cardiology, psychiatry, neurology, gastroenterology, diabetology, and respiratory ailments. Active Pharmaceuticals Ingredients (API) include peptides, steroids, hormones, and anti-cancer drugs and their quality is internationally approved. The international offices of Sun Pharmaceuticals Industries Ltd. are located in British Virgin Islands, Russia, and Bangladesh. In India, the offices are in Vapi, Silvassa, Panoli, Ahmednagar, and Chennai. Dilip S. Shanghvi is the Executive Chairman and managing Director of Sun Pharma and Kamalesh H. Shah is the secretary.
There are 3 major group companies of Sun Pharmaceuticals Industries are:
- Caraco Pharmaceuticals Laboratories (based in Detroit, Michigan)
- Sun Pharmaceuticals Industries Inc. (Michigan)
- Sun Pharmaceuticals (Bangladesh)
In 1983, when Sun Pharma was set up, it only dealt with two cities in India – West Bengal and Bihar. In 1985, it started trading nationally and by 2000, Sun Pharmaceuticals made its way through the international market. Products used in cardiology were manufactured in 1987 and at that time, Monotrate was one of the first products that was launched and went on to become a best-seller. In 1993, Sun Pharmaceuticals Industries set up their own research institute and named it SPARC. SPARC became popular by generating knowledge and honing process development skills across the world. In 1994, Sun Pharma enrolled itself in the main stock exchanges in India. Subsequently in 1995, the first API manufacturing plant was established at Panoli to mark its standard beyond competition and also capture the international market.
Sun Pharmaceuticals shifted its headquarters in Mumbai as it is at the center of Indian commercial trade. The company began its first international acquisition with an amount of US$ 7.5 million, acquiring Caraco Pharm Lab in Detroit. After 8 acquisitions by 2000, Sun Pharma established another research center at Mumbai with an objective to sharpen skills for the US market. Later on, the company introduced a few more treatment areas which include orthopedics, gynecology, and oncology.
Sun Pharma's speedy acclivity is one of its best attributes that has made it gain an international status across the world. It is always updated with the latest data and is highly competent. Quality remains the prime concern and is maintained strictly by the team. There are 3 forms of medicines manufactured plied by the company: oral, injectable, and delivery-system based. Caraco Pharm and the Halol Pharm Lab have got the approval of UKMHRA and USFDA in recent years.
Sun Pharmaceuticals was one of the first pharmaceutical firms to file an application to market a generic known as ANDA by assuring a 180-day marketing rights to formulate a more usual version of anti-ulcer drug in the US market. Sun Pharma shared this honorable 180-day achievement with Israel's Teva Pharmaceutical Industries. With such achievements, Sun Pharmaceutical Industries Limited is still ruling the pharmaceutical industry all across the world and is aiming high to gain popularity and success in brand building by making newer discoveries everyday.
Contact Us 
